Charles River Laboratories International, Inc. (CRL)
Market Cap | 10.38B |
Revenue (ttm) | 4.11B |
Net Income (ttm) | 438.82M |
Shares Out | 51.51M |
EPS (ttm) | 8.52 |
PE Ratio | 23.65 |
Forward PE | 17.42 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 422,006 |
Open | 203.10 |
Previous Close | 203.24 |
Day's Range | 201.09 - 204.61 |
52-Week Range | 161.65 - 275.00 |
Beta | 1.40 |
Analysts | Buy |
Price Target | 257.55 (+27.83%) |
Earnings Date | Aug 7, 2024 |
About CRL
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use o... [Read more]
Financial Performance
In 2023, CRL's revenue was $4.13 billion, an increase of 3.86% compared to the previous year's $3.98 billion. Earnings were $474.62 million, a decrease of -2.39%.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for CRL stock is "Buy." The 12-month stock price forecast is $257.55, which is an increase of 27.83% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/6/i/press5-2494887.jpg)
Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute at University of Colorado Anschutz Medical Campus
ROCKVILLE, Md.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral v...
![](https://cdn.snapi.dev/images/v1/f/d/press16-2482548.jpg)
CRL INVESTIGATION ALERT: Johnson Fistel LLP Investigates Charles River Laboratories' Directors and Officers for Breach of Fiduciary Duties
SAN DIEGO, CA / ACCESSWIRE / June 17, 2024 / Johnson Fistel, LLP (www.johnsonfistel.com), a shareholder rights law firm, announces its continuing investigation of whether certain directors and officer...
![](https://cdn.snapi.dev/images/v1/4/2/press2-2481812.jpg)
Charles River and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany, today announced a pl...
A.I. Impact On Biopharma: LLY, AMGN, TMO, CRL
The use of artificial intelligence across biopharma and life science tools and services is developing quickly. Will A.I. become a major disruptive technology in healthcare with the potential to signif...
![](https://cdn.snapi.dev/images/v1/h/s/press2-2473114.jpg)
Charles River Laboratories, in Collaboration With MatTek Corporation, Awarded Grant from the Foundation for Chemistry Research and Initiatives to Advance Research Alternatives
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces an integrated program, funded by a $1.3 million grant, to develop an in vitro alternative to inhalation toxicology studi...
![](https://cdn.snapi.dev/images/v1/8/f/press19-2465903.jpg)
Charles River Laboratories Expands Access to CRADL® Contract Vivarium Space in Somerville
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces the opening of a new CRADL® facility on Chestnut Street in Somerville, Massachusetts, an emerging life sciences hub.
![](https://cdn.snapi.dev/images/v1/n/y/press5-2461213.jpg)
Charles River Laboratories Announces Development of Nonclinical Virtual Control Groups with Sanofi to Reduce the Use of Animals in Research
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces the launch of its Virtual Control Groups (VCG) initiative with Sanofi to reduce the use of animals in research.
![](https://cdn.snapi.dev/images/v1/0/k/conf15-2458811.jpg)
Charles River Laboratories to Present at William Blair and Jefferies Conferences
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the William Blair 44th Annual Growth Stock Conference on Tuesday,...
![](https://cdn.snapi.dev/images/v1/a/a/press18-2453507.jpg)
Charles River Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the introduction of its Modular and Fast Track viral vector technology (tech) transfer fr...
![](https://cdn.snapi.dev/images/v1/p/z/press10-2449238.jpg)
Titian Receives Multi-Year Commitment from Charles River for Mosaic Sample Management Software
LONDON--(BUSINESS WIRE)-- #lifesciences--Titian Software and Charles River Laboratories have entered into a new 3-year partnership agreement, expanding Charles River's sample management capabilities. ...
![](https://cdn.snapi.dev/images/v1/s/z/press18-2421661.jpg)
Charles River Laboratories Announces First-Quarter 2024 Results
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL--Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2024. For the quarter, revenue was $1.01 bil...
![](https://cdn.snapi.dev/images/v1/l/v/press4-2405875.jpg)
Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its reference materials for adeno associated virus (AAV) and lentiviral vec...
![](https://cdn.snapi.dev/images/v1/d/u/press17-2382881.jpg)
Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--In addition to advancing human health and improving quality of life, we are dedicated to a responsible tomorrow.
![](https://cdn.snapi.dev/images/v1/x/p/press4-2373280.jpg)
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River launches the Alternative Methods Advancement Project (AMAP), an initiative to develop alternatives to reduce animal testing.
![](https://cdn.snapi.dev/images/v1/u/l/conf18-2368874.jpg)
Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL--Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2024 financial results on Thursday, May 9th, before the market opens....
![](https://cdn.snapi.dev/images/v1/j/u/press18-2367028.jpg)
Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology
WILMINGTON, Mass. & DUBLIN--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and Deciphex launch Patholytix Foresight, an AI-powered decision support tool for toxicologic pathology.
![](https://cdn.snapi.dev/images/v1/n/y/press7-2362857.jpg)
Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration wi...
![](https://cdn.snapi.dev/images/v1/i/r/press13-2356272.jpg)
Charles River to Perform Plasmid Production for Ship of Theseus
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus, a therapeutics company developing degradation-resistant homeobox (HOX) family biolog...
![](https://cdn.snapi.dev/images/v1/9/q/press1-2350753.jpg)
Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that its industry-leading team of oncology experts will attend the American Association f...
![](https://cdn.snapi.dev/images/v1/5/c/press3-2343708.jpg)
Charles River Laboratories Publishes 2023 Corporate Citizenship Report
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the publication of its 2023 Corporate Citizenship Report, which includes progress and res...
![](https://cdn.snapi.dev/images/v1/n/l/press11-2335030.jpg)
Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and National University of Singapore's (NUS) Yong Loo Lin School of Medicine (NUS Medicine), a leading me...
![](https://cdn.snapi.dev/images/v1/w/a/press14-2324168.jpg)
Charles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Navega Therapeutics, Inc., a biotechnology company developing epigenetic gene therapies, today announ...
![](https://cdn.snapi.dev/images/v1/0/l/conf14-2323044.jpg)
Epic Bio to Present at the Upcoming Charles River Cell and Gene Therapy Summit
SOUTH SAN FRANCISCO, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Epic Bio, a leading epigenetic editing company that plans to dose its first patients later this year, today announced that Amber Salzman...
![](https://cdn.snapi.dev/images/v1/2/o/conf16-2319817.jpg)
Charles River Laboratories to Present at Barclays Global Healthcare Conference
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CRL--Charles River Laboratories To Present At Barclays Global Healthcare Conference.
![](https://cdn.snapi.dev/images/v1/s/c/press11-2300341.jpg)
Wheeler Bio Seals Agreement with Charles River to Offer Portable CMC® to Discovery Clients to Accelerate Their Journey to First-in-Human Use
WILMINGTON, Mass. and OKLAHOMA CITY , Feb. 29, 2024 /PRNewswire/ -- Wheeler Bio, Inc., an agile contract development and manufacturing organization (CDMO), announced today a new strategic agreement wi...